Neohesperidin-dihydrochalcone-Neohesperidin-DC-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁(yè)
Neohesperidin-dihydrochalcone-Neohesperidin-DC-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁(yè)
Neohesperidin-dihydrochalcone-Neohesperidin-DC-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁(yè)
Neohesperidin-dihydrochalcone-Neohesperidin-DC-DataSheet-生命科學(xué)試劑-MedChemExpress_第4頁(yè)
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemENeohesperidin dihydrochalconeCat. No.: HY-N0154CAS No.: 20702-77-6Synonyms: Neohesperidin DC; NHDC分式: CHO分量: 612.58作靶點(diǎn): Reactive Oxygen Species作通路: Immunology/Inflammation; Metabolic Enzyme/Protease; NF-B儲(chǔ)存式: Powder -20C 3 years

2、4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 31 mg/mL (50.61 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.6324 mL 8.1622 mL 16.3244 mL5 mM 0.3265 mL 1.6324 mL 3.2649 mL10 mM 0.1632 mL 0.8162 mL 1.6324 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液

3、,并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Neohesperidin dihydrochalcone種合成的糖苷查酮,作為低熱量造甜味劑添加到各種品和飲料中。體外研究Neohesperidin dihydrochalcone shows remarkable radical scavenging activity against stable radical andreactive oxygen species (ROS) in concentration dependent manner. Especially, neohesperidin1/3 Mast

4、er of Small Molecules 您邊的抑制劑師www.MedChemEdihydrochalcone is the most potent inhibitor of H2O2 and HOCl. Neohesperidin dihydrochalcone shows HOClscavenging activity of 93.5% and H2O2 scavenging property of 73.5%. Neohesperidin dihydrochalconeshows extensive inhibitory effect especially on non-radical

5、 ROS H2O2 and HOCl with IC50 values of 205.1,25.5 M 1. Neohesperidin dihydrochalcone is found to be an activator of porcine pancreatic alpha-amylase(PPA) with an IC50 of 389 M 2.體內(nèi)研究 Neohesperidin dihydrochalcone administration results in significant reduction in activities of two usefulmarkers of l

6、iver damage, AST and ALT. The relative levels of NF-B, IL-6, IL-1 and TNF- protein in theliver of PQ-treated mice are inhibited by neohesperidin dihydrochalcone 3. The embryotoxicity/teratogenicityof neohesperidin dihydrochalcone is examined in Wistar Crl:(WI)WU BR rats. No adverse effects areobserv

7、ed at neohesperidin dihydrochalcone levels of up to 5% of the diet, the highest dose level tested, atwhich the rats consumed about 3.3 g/kg body weight/day 4.PROTOCOLCell Assay 1 WST-8 dye is used in the cell viability assay. HIT-T15 and HUVEC cells are grown and maintained inDulbeccos modified Eagl

8、es medium, supplemented with 10% fetal bovine calf serum. 1000 cells in eachwell are incubated with various concentrations of neohesperidin dihydrochalcone (50, 100, 500 M, 1 mM)and other compounds. After treating HIT-T15 and HUVEC cells with 500 M HOCl, WST-8 dye is added toeach well, and the absor

9、bance is detected at 420 nm with microplate reader 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Rats: The embryotoxicity/teratogenicity of neohesperidin dihydrochalcone is examined in Wistar Crl:(WI)WUAdministration 34 BR rats. The study is

10、comprised of four groups of 28 mated female rats each, i.e., a control group (0%neohesperidin dihydrochalcone) and three treatment groups (1.25, 2.5, and 5% neohesperidindihydrochalcone). The general condition and behavior of the animals are observed twice daily. Body weightis determined on days 0,

11、7, 14, and 21 of gestation. Food consumption is determined during threeconsecutive periods (days 0-7, 7-14, and 14-21 of gestation) 4.3Mice: Neohesperidin dihydrochalcone is dissolved in a 0.5% CMC vehicle. Mice are randomized into fourgroups. The control group receives equal volume of vehicles thro

12、ughout. The PQ group receives saline oncedaily for 6 consecutive days. One hour after final saline treatment, mice are injected with PQ (75 mg/kg bodyweight). The neohesperidin dihydrochalcone group receives a daily dose of 200 mg/kg body weight by oralgavage for 6 consecutive days. One hour after f

13、inal neohesperidin dihydrochalcone treatment, mice areinjected with PQ (75 mg/kg body weight) 3.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Choi JM, et al. Antioxidant properties of neohesperidin dihydrochalcone: inhibition of hypochlor

14、ous acid-induced DNA strand breakage,protein degradation, and cell death. Biol Pharm Bull. 2007 Feb;30(2):324-30.2. Kashani-Amin E, et al. Neohesperidin dihydrochalcone: presentation of a small molecule activator of mammalian alpha-amylase as anallosteric effector. FEBS Lett. 2013 Mar 18;587(6):652-

15、8.3. Shi Q, et al. Artificial sweetener neohesperidin dihydrochalcone showed antioxidative, anti-inflammatory and anti-apoptosis effects2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEagainst paraquat-induced liver injury in mice. Int Immunopharmacol. 2015 Dec;29(2):722-9.4. Waalkens-Berendsen DH, et al. Embryotoxicity and teratogenicity study with neohesperidin dihydrochalcone in rats. Regul ToxicolP

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論